Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use. Patients treated with enzalutamide prior to Lu-PSMA therapy had higher mean SUV values before treatment with 18 F-DCFPyL. 68Ga-PSMA-11 and FDG-PET/CT scans were compared with scans from the VISION trial to assess patient eligibility for Pluvicto. The care management plans for several patients were changed after those patients underwent PSMA PET/CT. A research team developed a study to implement aPROMISE for the evaluation of PSMA and FDG-PET/CT scans acquired before RLT. A team of researchers compiled optimized methods for post-treatment radiation precautions for patients receiving Pluvicto. New research identified genomic features and post-therapeutic SPECT/CT parameters as predictors of response to Pluvicto. A study compared bone marrow dosimetry using three different methods for patients treated with 177Lu-PSMA-617. The proposed method of algorithm-based TTV produced comparable TTV and whole-body SUVmean levels. Researchers compared the performance of Ga-68 PSMA PET/CT vs F-18-NaF PET/CT in detecting bone metastases in prostate cancer. An encoder-decoder network employing 3-dimensional convolutions was trained to segment regions that were suspected of cancer.